Exemestane, a new steroidal aromatase inhibitor of clinical relevance

Area of Science:

• Endocrinology
• Oncology
• Medicinal Chemistry

Background:

• Breast cancer is a leading cause of death in women, with estrogen contributing to tumor growth.
• Inhibition of estrogen biosynthesis via aromatase inhibitors is a key therapeutic strategy for hormone-dependent breast cancer.

Purpose of the Study:

• To present the design, synthesis, and review the biochemical, pharmacological, and clinical data of exemestane.
• To highlight exemestane as a novel steroidal irreversible aromatase inhibitor.

Main Methods:

• Discussion of laboratory and viable syntheses of exemestane from steroidal precursors.
• Review of biochemical and pharmacological studies.
• Brief review of clinical impact.

Main Results:

• Exemestane (Aromasin) is a novel steroidal irreversible aromatase inhibitor.
• The drug is orally active and well-tolerated.
• Effective for postmenopausal patients with advanced breast cancer refractory to standard therapies.

Conclusions:

• Exemestane represents an effective therapeutic option for hormone-dependent breast cancer.
• It provides a well-tolerated oral hormonal therapy for advanced, refractory cases in postmenopausal women.